PIK3C2B inhibition improves function and prolongs survival in myotubular myopathy animal models

Area of Science:

• Biochemistry
• Genetics
• Neurology

Background:

• Myotubular myopathy (MTM) is a severe pediatric neuromuscular disease caused by MTM1 gene mutations, affecting phosphoinositide (PIP) metabolism.
• Previous studies indicated phosphatidylinositol-3-phosphate (PI3P) accumulation in MTM animal models.
• Currently, no effective treatments exist for MTM.

Purpose of the Study:

• To investigate if reducing PI3P levels could prevent or reverse MTM.
• To identify specific PI3-kinases (PI3Ks) that modify the MTM disease process.
• To evaluate PI3K inhibition as a potential therapeutic strategy for MTM.

Main Methods:

• Utilized an MTM1-deficient mouse model with muscle-specific genetic targeting of class II and III PI3 kinases (PIK3C2B and PIK3C3).
• Confirmed findings in zebrafish models, testing PI3K inhibitors for efficacy.
• Administered the PI3K inhibitor wortmannin to Mtm1-deficient mice to assess therapeutic effects on motor function and lifespan.

Main Results:

• Muscle-specific ablation of Pik3c2b, but not Pik3c3, completely prevented MTM in mice.
• Post-symptomatic targeting of Pik3c2b led to significant disease rescue in MTM mice.
• PI3K inhibitors prevented MTM development in zebrafish, and wortmannin improved motor function and survival in MTM mice.

Conclusions:

• PIK3C2B acts as a genetic modifier of MTM, and its inhibition is a promising therapeutic approach for MTM.
• This study validates targeting PI3K pathways as a treatment strategy for MTM.
• The findings support exploring similar strategies for other PIP metabolic disorders and highlight the therapeutic potential of targeting modifier gene pathways.